You don't need to list the above, I am fully aware of that. So...

You don't need to list the above, I am fully aware of that. So are the ones who got the funds. And they aren't interested at all. Not one wants it for free. They could buy a big stake for a few millions, just to secure their share in case it turns out to be a hit. But nobody is interested. Hopper had lined up one or more in May and it collapsed. No one else jumped in - that is the truth. Follow the science as $$$ follow the science. neither at IMU nor CHM the $$$ are following the science. You can have the best treatment in the world, if nobody wants it, you are screwed. Of course it may change, but how likely is it? IMU misjudged the market with the B-cell platform. It works well, even better than Herceptin and Keytruda and yet, no partner or buyer - shelfed. Now look at CHM 1101. Where are the offers? Deprioritized due to lack of funds. Great results but no interest. That's the fact and that shouldn't be ignored when it comes to financial investments.

I could be wrong, kicking my arse in the future for missing out. But atm all indicators are negative. Otherwise CHM and IMU would get inundated with $$$$, especially at an almost ZERO CHM valuation. The ASX ignoring CHM isn't an indicator, but the US funds and pharma, including Dr Bec's expert friends, ignoring CHM, definitely is.

I sold out due to the stated above. Not down ramping, just my thoughts. Of course I can re-buy at any time should I recognise that I was wrong. But just the CR is a hurdle. If approved, 2 x 800m shares / oppies want to be invested profitable. If the sp won't hold above 1c - watch them dumped. And if it won't get approved - no money. Both ways, can't see any upside as both AML - trial results so far failed to excite the market, GBM is on hold and CDH 17 must have dosed at least 6 patients which could mean waiting until mid '25. Now you guys do the Math.

GLTA